Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next

As you might know, Epigral Limited (NSE:EPIGRAL) recently reported its first-quarter numbers. Revenues were ₹6.1b, approximately in line with whatthe analyst expected, although statutory earnings per share (EPS) crushed expectations, coming in at ₹37.25, an impressive 98% ahead of estimates. Earnings are an important time for investors, as they can track a company's performance, look at what the analyst is forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analyst is expecting for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Following the latest results, Epigral's solitary analyst are now forecasting revenues of ₹28.6b in 2026. This would be a notable 14% improvement in revenue compared to the last 12 months. Statutory per-share earnings are expected to be ₹98.30, roughly flat on the last 12 months. Yet prior to the latest earnings, the analyst had been anticipated revenues of ₹31.0b and earnings per share (EPS) of ₹96.80 in 2026. So it looks like the analyst has become a bit less optimistic after the latest results announcement, with revenues expected to fall even as the company is supposed to maintain EPS.

Check out our latest analysis for Epigral

The consensus price target rose 6.1% to ₹2,600, with the analyst apparently satisfied with the business performance despite lower revenue forecasts.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Epigral's rate of growth is expected to accelerate meaningfully, with the forecast 19% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 8.6% p.a. over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 13% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Epigral is expected to grow much faster than its industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analyst holding their earnings forecasts steady, in line with previous estimates. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. Still, earnings are more important to the intrinsic value of the business. There was also a nice increase in the price target, with the analyst clearly feeling that the intrinsic value of the business is improving.

With that in mind, we wouldn't be too quick to come to a conclusion on Epigral. Long-term earnings power is much more important than next year's profits. We have analyst estimates for Epigral going out as far as 2028, and you can see them free on our platform here.

It might also be worth considering whether Epigral's debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.